Piper Sandler Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Milestone Pharmaceuticals (NASDAQ:MIST) but lowered the price target from $6 to $5.

March 05, 2024 | 2:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler maintains an Overweight rating on Milestone Pharmaceuticals but lowers the price target from $6 to $5.
While the maintenance of an Overweight rating suggests continued confidence in Milestone Pharmaceuticals' fundamentals and growth prospects, the reduction in the price target could reflect adjustments in valuation metrics or market conditions. This mixed signal might lead to short-term uncertainty among investors, potentially causing minor fluctuations in the stock price. However, the overall positive outlook is likely to support the stock's performance in the near term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100